Trianglenuzefatide pevedotin (BT5528) (NCT07450859)
nuzefatide pevedotin (BT5528) trial for Pancreatic Ductal Adenocarcinoma (PDAC) (NCT07450859). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with metastatic pancreatic ductal adenocarcinoma that progressed after one treatment line, or after a second line using a KRAS inhibitor. Prior pancreatic taxane treatment or any MMAE drug excludes participation.
The idea: nuzefatide pevedotin targets EphA2 to deliver the anticancer drug MMAE. Everyone receives an intravenous infusion every two weeks. Researchers measure tumor responses, side effects and drug processing.
This phase 2 study plans 39 patients. BicycleTx sponsors it; six US sites are recruiting, including Phoenix.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.